aspirin has been researched along with Familial Primary Pulmonary Hypertension in 1 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Familial Primary Pulmonary Hypertension: Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawut, SM | 1 |
| Bagiella, E | 1 |
| Shimbo, D | 1 |
| Lederer, DJ | 1 |
| Al-Naamani, N | 1 |
| Roberts, KE | 1 |
| Barr, RG | 1 |
| Post, W | 1 |
| Horn, EM | 1 |
| Tracy, R | 1 |
| Hassoun, P | 1 |
| Girgis, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension[NCT00384865] | Phase 2 | 64 participants (Actual) | Interventional | 2006-09-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Please refer to the Adverse Event Tables for specific information (NCT00384865)
Timeframe: Measured at 6 months
| Intervention | events (Number) |
|---|---|
| Aspirin 81 mg | 59 |
| Aspirin Placebo | 66 |
| Simvastatin 40 mg | 66 |
| Simvastatin Placebo | 58 |
(NCT00384865)
Timeframe: Measured at 6 months
| Intervention | meters (Least Squares Mean) |
|---|---|
| Aspirin 81 mg | 438.0 |
| Aspirin Placebo | 438.5 |
| Simvastatin 40 mg | 425.0 |
| Simvastatin Placebo | 452.7 |
Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death. (NCT00384865)
Timeframe: Measured at 6 months
| Intervention | events (Number) |
|---|---|
| Aspirin 81 mg | 2 |
| Aspirin Placebo | 6 |
| Simvastatin 40 mg | 4 |
| Simvastatin Placebo | 4 |
1 trial available for aspirin and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Data Interpretatio | 2011 |